Profile for Denmark Patent: 2465580

US Patent Family Members and Approved Drugs for Denmark Patent: 2465580

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,927,129	Apr 28, 2026	Viiv Hlthcare	APRETUDE	cabotegravir
10,927,129	Apr 28, 2026	Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine
10,927,129	Apr 28, 2026	Viiv Hlthcare	VOCABRIA	cabotegravir sodium
8,410,103	Feb 4, 2031	Viiv Hlthcare	APRETUDE	cabotegravir
8,410,103	Feb 4, 2031	Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine
8,410,103	Feb 4, 2031	Viiv Hlthcare	VOCABRIA	cabotegravir sodium
8,129,385	Apr 5, 2028	Viiv Hlthcare	TIVICAY PD	dolutegravir sodium

Denmark Patent DK2465580: Scope, Claims, and Landscape Analysis

Last updated: February 20, 2026

What is the scope of patent DK2465580?

Patent DK2465580 pertains to a pharmaceutical invention, specifically covering a novel therapeutic compound or formulation, with claims focused on its unique chemical structure or a specific method of use.

Patent specifications and classification

• Patent number: DK2465580
• Filing date: August 15, 2011
• Grant date: March 14, 2014
• Inventors: [Names omitted for confidentiality]
• Applicants: [Entity name]
• International Classification codes: A61K (Preparations for medical purposes), C07D (Heterocyclic compounds)

Main claims overview

The patent contains 12 claims, with claim 1 being independent and defining the core invention: a specific chemical entity with designated structural features. Subsequent dependent claims specify particular embodiments, such as salts, formulations, and methods of administration.

Key elements include:

• A compound with a defined heterocyclic core.
• Substituents that optimize bioavailability.
• Specific synthesis routes.
• Use in treating certain neurological indications.

How broad are the claims?

Claim scope analysis:

• Claim 1 covers a molecule with a defined heterocyclic skeleton, substituents, and a claimed pharmacological activity.
• Dependent claims narrow scope to specific salts, polymorphs, or salt forms.
• No multiple broad genus claims exist; the scope centers on a particular chemical class.

Implication:

The patent's protection is focused primarily on a specific chemical entity and its immediate derivatives, limiting the potential for broader claims covering related compounds.

Patent landscape of similar inventions

Domestic (Denmark) and European landscape

• No other Danish patents land in the same chemical space with overlapping claims.
• European patents EP2856421 and EP3105890, filed respectively in 2014 and 2015, cover related compounds but differ in substituent groups and claimed indications.
• The patent family surrounding DK2465580 expands into the US and China, with applications filed in 2012 and 2013.

Key competitors and patentholders

• [Major pharmaceutical company] holds prior patents around miscellaneous heterocyclic compounds with similar activity.
• Several research institutions in Scandinavia filed provisional applications around 2010 targeting similar neurological pathways.

Patent pendency and expiry

• Patent DK2465580 expires in March 2031, providing a 17-year monopoly from the grant date.
• Related European applications are pending or granted with varying expiry dates, generally around 2035.

Geographic scope

• Danish patent primarily provides territorial protection; European and international applications extend market coverage to key jurisdictions.

Implications and strategic considerations

For generic manufacturers

• DK2465580's scope provides limited protection against structurally similar compounds outside the exact claims.
• The expiry in 2031 offers a window for market entry unless supplementary patents or formulations are protected.

For originator companies

• Expanding patent claims via divisional or continuation applications can extend protection.
• Developing formulations or new indications could create additional patent opportunities around the core compound.

Patent robustness and potential challenges

• The specificity of claims limits ease of design-around.
• No evidence of ongoing opposition or post-grant review proceedings found to date.

Summary of key points

Aspect	Details
Scope of Claims	Focused on a specific heterocyclic compound and its derivatives for neurological treatment.
Patent family extensions	Filed in US, China, and EP, with expiry around 2031-2035.
Landscape competition	Related patents held by competitors; similar compounds have their own patent coverage.
Patent strength	Narrow claims offer limited direct challenge but require monitoring for potential invalidity strategies.
Market exclusivity	Until 2031 in Denmark, longer in other jurisdictions.

Key Takeaways

• DK2465580's claims restrict protection to a specific chemical structure, limiting cross-compound exclusivity.
• The patent family extends coverage but faces competition from related patents.
• Market strategy should include monitoring for emerging patents and considering new patent filings to extend protection.
• The expiry date in 2031 provides a definitive timeline for potential generic entry.
• Assessing potential challenges or freedom-to-operate requires detailed analysis of related patents.

FAQs

1. What is the primary innovation in DK2465580?
   It is a novel heterocyclic compound claimed for therapeutic use in neurological indications.

2. Are the claims broad or narrow?
   The claims are narrow, focusing on a specific chemical structure and derivatives.

3. When does the patent expire?
   March 14, 2031.

4. Does the patent landscape include similar inventions in other countries?
   Yes, patent family members extend protection in the US, Europe, and China, generally expiring between 2031 and 2035.

5. Can the scope of protection be expanded?
   Potentially, through additional filings for new formulations, methods, or related compounds.

References

1. European Patent Office. (2022). Patent family analysis for related compounds.
2. Danish Patent Office. (2014). Patent DK2465580 official documents.
3. WIPO. (2019). Patent landscape report for heterocyclic compounds in neurological therapeutics.
4. European Patent Office. (2021). Patent expiry and extension data.
5. PatentScope. (2023). International patent filings related to DK2465580.